Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at some of what’s been happening: A good report for Vumerity Final results are in from the EVOLVE-MS-1 clinical trial for patients with…
The MS Wire — Ed Tobias
People say to write what you know and Ed Tobias knows about MS. He’s lived with the illness since 1980, when he was 32 years old. Ed’s a retired, award-winning broadcast journalist and his column combines his four decades of MS experiences with news and comments about the latest in the MS community. In addition to writing his column, Ed is one of the patient moderators on the MS News Today Facebook, Twitter, and Instagram sites. He’s also the author of “The Multiple Sclerosis Toolbox: Hints and Tips for Living with M.S.” Ed and his wife split their time between the Washington, D.C. suburbs and Florida’s Gulf Coast, trying to follow the sun.
Featured Post
This is my 823rd column for Multiple Sclerosis News Today. It is also my last. Over the past seven and a half years, I’ve written about multiple sclerosis (MS) fatigue and frustration, about treatments and travel, about neurologists (good and bad), stress,…
For someone with multiple sclerosis (MS), going to a venue to see a concert or sporting event can be an experience filled with uncertainty — especially if, like me, they’re using a mobility aid. For me to do it, I have to ask myself several questions: How will I…
Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at some of what’s been happening. MS relapses and COVID-19 Since COVID-19 became a concern over three years ago, I’ve read many comments…
It wasn’t a good morning. I was dragging my cement-pillar legs around the kitchen and grew frustrated as I lurched from the refrigerator to the counter to feed the cat and the dog. I’d propped my two canes against the counter, but they’d slid to the floor — not once,…
Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: ATA188 fails a big test ATA188 is an experimental cell therapy developed by Atara Biotherapeutics aimed at easing MS…
Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Lemtrada or stem cell transplant? While the U.S. Food and Drug Administration has not yet approved stem cell transplants…
I slept through the night last night. Recently, I’ve managed to do that on most nights. No 4 a.m. bathroom trips for me! That’s a big deal. There was a time when I’d get up two or even three times during the night for a bladder run. Sleeping seven or…
Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Dalfampridine side effects The side effects that might occur if you use dalfampridine (sold under the brand name Ampyra)…
I’m back in my happy place. My wife, Laura, and I, along with our Yorkie-poo and our Maine Coon cat, have made it back to our Florida home after 16 hours and about 1,000 miles of driving over two days. There were no traffic jams, we had a comfortable motel…
Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. This week, the stories cover research presented at the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the…
“I’m so tiredThe hammer’s coming down againI’m hardwiredAll the signals cross and double backBroken insideThere’s no fixing anythingHow do i explainI’m fighting every day to do the simple things?” The lyrics to “Hammer,” written by singer Susie Ulrey and the band Pohgoh,…
Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. This week, the stories cover research presented at the joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the…
My mobility scooter died last week. I can walk 100 feet or so using a pair of canes, but my wheels are usually my legs. So when I turned the key and discovered those “legs” were powerless, I was in a bind. This breakdown couldn’t have happened at a worse…
Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: ‘Silent’ MS progression Readers of the MS News Today website and Facebook page sometimes wonder why their MS…
You’d think that people with multiple sclerosis (MS) and other disabilities would have easy access to healthcare services. That’s not always so. A small study in the journal Health Affairs that I wrote about last year said many physicians “expressed explicit bias toward people with disabilities and described…
Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Stem cell transplant found to be safe, effective in recent study Autologous hematopoietic stem cell transplant (aHSCT) has been…
My wife and I got the latest COVID-19 vaccine the other day, the first of three vaccines we’ll be getting this fall. The others are the seasonal flu vaccine and the respiratory syncytial virus (RSV) vaccine. This was my sixth COVID-19 vaccine, and I’ve received a…
Welcome to “MS News Notes,” a column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: An ‘inverse vaccine’ trial to treat MS What’s an “inverse vaccine,” you might ask? While traditional vaccines rev up…
A question that’s been bothering me lately is this: It seems that more than a few neurologists have a less than optimal understanding of multiple sclerosis (MS). Why is that? In my four decades of living with MS, and during the several years I’ve written this column…
Explore More Columns
Discussion
Discussion
Discussion